Report Ocean’s latest analysis delves into the “Vietnam Fabry Disease Treatment Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, segmentation ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

Background: Neuropathic pain is one of the key features of (classical) Fabry disease (FD). No randomized clinical trials comparing effectiveness of different pain management strategies have been ...

In plants, the space between cells is a key battleground during infection. To avoid recognition in this space, a strain of ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for Huntington's ...

Biosidus’ commitment to global biosimilar access With over 40 years of experience in the development, production, and commercialization of biosimilars, Biosidus remains dedicated to improving global ...

In plants, the space between cells is a key battleground during infection. To avoid recognition in this space, a strain of the bacterial tomato disease Pseudomonas syringae manipulates plants by ...

After 26 weeks of treatment, the study successfully met its primary endpoint, underscoring the potential of agalsidase beta as a safe and effective biosimilar treatment for Fabry disease.